Professor Leonie Young is working to determine whether some secondary breast cancers that have spread to the brain could be treated with drugs called PARP inhibitors. She hopes that more people could benefit from this type of treatment.

Professor Janet Brown wants to determine if combining an immunotherapy drug avelumab with another drug, radium-233, could make the treatment more effective. She hopes this combination will improve the immune response to secondary breast cancer in the bone and at other sites in the body.

It’s thought that turning on the androgen receptor in some oestrogen receptor positive (ER+) breast cancers could help stop tumour growth. Dr Violeta Serra is investigating this theory further and is testing whether the androgen receptor could be a new treatment target.

Palbociclib is a drug given to people with secondary, oestrogen receptor positive (ER+) breast cancer to help manage their disease. Dr Saskia Wilting is trying to find out who will benefit from taking this drug and why some cancers do not respond to it.

Professor Chris Lord is investigating how breast cancers with changes in BRCA genes can become resistant to a group of drugs called PARP inhibitors. He hopes to improve treatments for people with this type of breast cancer.

Professor Simak Ali and Dr Lesley-Ann Martin are investigating how proteins called CDKs play a part in cancer’s resistance to palbociclib – a drug used to treat oestrogen receptor positive (ER+) secondary breast cancer. He is exploring whether blocking a protein called CDK7 could be a new way to treat tumours that have become resistant to palbociclib.